Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,243
  • Shares Outstanding, K 31,196
  • Annual Sales, $ 80 K
  • Annual Income, $ -48,820 K
  • EBIT $ -45 M
  • EBITDA $ -44 M
  • 60-Month Beta 0.07
  • Price/Sales 431.35
  • Price/Cash Flow N/A
  • Price/Book 0.91

Options Overview Details

View History
  • Implied Volatility 467.20% ( +36.31%)
  • Historical Volatility 80.80%
  • IV Percentile 98%
  • IV Rank 72.93%
  • IV High 623.58% on 12/09/24
  • IV Low 45.90% on 07/11/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 134
  • Volume Avg (30-Day) 40
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 2,618
  • Open Int (30-Day) 2,516

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.35
  • Number of Estimates 2
  • High Estimate -0.29
  • Low Estimate -0.42
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -6.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +17.27%
on 12/19/24
1.5400 -16.23%
on 11/25/24
-0.1000 (-7.19%)
since 11/20/24
3-Month
1.1000 +17.27%
on 12/19/24
1.9700 -34.52%
on 11/11/24
-0.5100 (-28.33%)
since 09/20/24
52-Week
1.1000 +17.27%
on 12/19/24
10.2400 -87.40%
on 05/14/24
-3.3600 (-72.26%)
since 12/20/23

Most Recent Stories

More News
Amarin's Q3 Earnings In Line, Revenues Fall Shy of Estimates

Amarin Corporation plc AMRN reported an adjusted loss of 5 cents per share for the third quarter of 2024, which was in line with the Zacks Consensus Estimate. The company had reported breakeven earnings...

FOLD : 9.80 (+0.72%)
AMRN : 0.4600 (-1.18%)
ARDX : 4.82 (+2.77%)
ATNM : 1.2900 (+15.18%)
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Corcept Therapeutics Incorporated CORT reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of...

FOLD : 9.80 (+0.72%)
CORT : 51.40 (+0.49%)
ARDX : 4.82 (+2.77%)
ATNM : 1.2900 (+15.18%)
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the second of a...

ATNM : 1.2900 (+15.18%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END

ATNM : 1.2900 (+15.18%)
BPTH : 1.2600 (-15.44%)
LGVN : 1.6500 (+3.12%)
SLS : 0.8880 (-1.11%)
BMY : 57.33 (+1.83%)
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase

ATNM : 1.2900 (+15.18%)
BPTH : 1.2600 (-15.44%)
LGVN : 1.6500 (+3.12%)
SLS : 0.8880 (-1.11%)
BMY : 57.33 (+1.83%)
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END

SNDX : 13.08 (+1.79%)
ATNM : 1.2900 (+15.18%)
KURA : 9.01 (+0.45%)
BMEA : 4.23 (+3.68%)
JNJ : 144.47 (+0.62%)
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies

SNDX : 13.08 (+1.79%)
ATNM : 1.2900 (+15.18%)
KURA : 9.01 (+0.45%)
BMEA : 4.23 (+3.68%)
JNJ : 144.47 (+0.62%)
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at developments for the...

ATNM : 1.2900 (+15.18%)
Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress

Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors Combination with leading menin inhibitor...

ATNM : 1.2900 (+15.18%)
Actinium Pharma Highlights Three Abstracts Accepted for Poster Presentation at the SOHO 2023 Annual Meeting

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

ATNM : 1.2900 (+15.18%)

Business Summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application for their ARCs is targeted conditioning, which is intended...

See More

Key Turning Points

3rd Resistance Point 1.5100
2nd Resistance Point 1.4000
1st Resistance Point 1.3450
Last Price 1.2900
1st Support Level 1.1800
2nd Support Level 1.0700
3rd Support Level 1.0150

See More

52-Week High 10.2400
Fibonacci 61.8% 6.7485
Fibonacci 50% 5.6700
Fibonacci 38.2% 4.5915
Last Price 1.2900
52-Week Low 1.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar